Stock Analysis
Novartis AGNVS
P/E 20.47×· 5Y range 7.02–33.14×· 61th percentile of history
Sector: Healthcare · Industry: Drug Manufacturers - General
AnalystsHold34 analystsP/E 20.5× sits at the 61st percentile of its 5.086926762491444-year history.
Cash covers 16% of debt · FY 2025.
PMP Verdict
High quality, fairly valued
Strengths
- Profitability95
- Quality92
Risks
- Growth37
Strong fundamentals at a reasonable valuation.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 3.6 — safe-zone balance sheet
- ✓ROE 33.3% — efficient capital deployment
- ✓Interest coverage 16.4× — debt well covered
What's happening with NVS
Profile
Strong moat, profitability and earnings quality; growth lags behind.
How is each axis scored?
- Valuation57/100 · Moderate
- P/E vs own history (61th pct)5/25
- FCF yield (5.9%)20/25
- P/S (5.0x)20/25
- EV/EBIT (17.0x)12/25
- Growth37/100 · Weak
- Revenue CAGR (6.5%)12/25
- Net income CAGR (-12.7%)0/25
- EPS CAGR 5Y (-9.4%)0/25
- Fwd implied growth (33.4%)25/25
- Profitability95/100 · Strong
- ROIC (18.0%)20/25
- ROE (33.3%)25/25
- Net margin (24.7%)25/25
- Operating margin (33.5%)25/25
- Financial Health61/100 · Moderate
- Altman Z (3.59)25/25
- Current ratio (0.86)6/25
- Interest coverage (16.4x)25/25
- Net cash / debt (D/A 34%)5/25
- Quality92/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.77)25/25
- FCF conversion (120%)25/25
- Margin stability (σ 5.0%)20/25
- Moat100/100 · Strong
- ROIC >12% years (5/5 yrs)25/25
- Median gross margin (74.1%)25/25
- FCF-positive years (5/5 yrs)25/25
- Worst-year net margin (worst 16.0%)25/25
About Novartis AG
Novartis develops and manufactures innovative drugs. Show more
Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Employees: 75,267 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
57CP/E (TTM)20.2xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 7.0x–33.1x · 61st pct
P/FCF18.1xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield5.9%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 5.1%–8.9% · 12th pct
P/S (TTM)4.98xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 3.8x–5.8x · 74th pct
EV/EBIT17.0xB
Grade B: FairEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 13.6x–26.5x · 21st pct
EV/Sales5.5xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E15.1xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio6.72xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.48D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield3.35%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio141.3%D
Grade D: UnsustainableDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
95A+ROIC18.0%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE33.3%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA11.1%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin24.7%A
Grade A: HighNet Income / Revenue
Operating Margin33.5%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin76.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin29.6%A
Grade A: HighFCF / Revenue
True FCF Margin27.6%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
37DRevenue CAGR6.5%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-12.7%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-9.4%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth33.4%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income8.1%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue2.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
61BAltman Z-Score3.59A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio0.86xD
Grade D: LowCurrent Assets/Liabilities
Quick Ratio0.67xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage16.4xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment2.5yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT2.2xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity1.17xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.16xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
92A+Piotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.77A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion119.9%A
Grade A: StrongFCF / Net Income
Margin Stability5.0%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue2.9%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.49xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
100A+ROIC >12% Years5/5 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)74.1%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years5/5 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor16.0%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$7.36
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$4.01
Cash & short-term investments per share (Finnhub)
Book Value / Share$21.86
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$49.01B
Total debt obligations (short + long term)
Cash & Equiv.$7.62B
Cash and short-term investments
Net Debt$41.40B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$41.95B
Shareholders' equity (book value)
Asset / Liability1.52xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$282.07B
Current Market Capitalization
Beta1.35C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Dec 2025 · Ratio snapshot Oct 17, 2026
Key Insights: Novartis AG (NVS)
Novartis AG meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 3.59 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.77 suggests a low likelihood of earnings manipulation. Novartis AG converts about 30% of revenue into free cash flow — strong cash generation.
- Takes ~2.5 years to repay net debt from free cash flow.
- Return on equity of 33.3% is well above the market average.
- The stock currently yields 3.4% in dividends.
See how NVS ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all NVS moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 150.66 | +2.57% | 2.06 |
| Oct 14 | Regular | 146.84 | +3.11% | 3.05 |
| Oct 14 | After-hours | 146.88 | +3.14% | 3.08 |
Frequently Asked Questions about NVS
What is the current Novartis AG (NVS) stock price?
NVS is trading at $150.62 at the last market close, up 0.16% on the session. PreMarketPrice tracks NVS pre-market, intraday and after-hours prices.
Is NVS stock a buy right now?
PreMarketPrice's quantitative model rates Novartis AG's financial health at 61/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is NVS stock overvalued?
Novartis AG trades at a trailing P/E of 20.2 and our valuation score rates it 57/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Novartis AG report earnings?
No confirmed earnings date is currently scheduled for NVS. The Earnings section lists recent reports and updates as dates are announced.
What sector does Novartis AG operate in?
Novartis AG operates in the Healthcare sector, within the Drug Manufacturers - General industry. The Related Stocks section lists sector peers for comparison.
What does Novartis AG do?
Novartis develops and manufactures innovative drugs.
About Novartis AG (NVS) Stock
Novartis AG (NVS) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry. As of the latest update, Novartis AG is trading at $150.62, up 0.16% on the day with a market capitalization of $282.1 billion. The financial health score for NVS is 61/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for NVS stock.
NVS Stock Analysis & Key Metrics
On PreMarketPrice, you can track Novartis AG (NVS) across multiple dimensions:
- Pre-market price & movement: Real-time NVS stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for NVS with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Novartis AG across multiple reporting periods.
- Financial health score: A composite score of 61/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for NVS.
- Sector peers: Compare NVS against 6 other healthcare stocks on key financial metrics.
Is NVS a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Novartis AG (NVS) as an investment. The financial health score of 61/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Novartis AG (NVS) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.